Cellular therapeutics for heart failure

Focus on mesenchymal stem cells

Amitabh C. Pandey, Jordan J. Lancaster, David T. Harris, Steven Goldman, Elizabeth B Juneman

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Resulting from a various etiologies, the most notable remains ischemia; heart failure (HF) manifests as the common end pathway of many cardiovascular processes and remains among the top causes for hospitalization and a major cause of morbidity and mortality worldwide. Current pharmacologic treatment for HF utilizes pharmacologic agents to control symptoms and slow further deterioration; however, on a cellular level, in a patient with progressive disease, fibrosis and cardiac remodeling can continue leading to end-stage heart failure. Cellular therapeutics have risen as the new hope for an improvement in the treatment of HF. Mesenchymal stem cells (MSCs) have gained popularity given their propensity of promoting endogenous cellular repair of a myriad of disease processes via paracrine signaling through expression of various cytokines, chemokines, and adhesion molecules resulting in activation of signal transduction pathways. While the exact mechanism remains to be completely elucidated, this remains the primary mechanism identified to date. Recently, MSCs have been incorporated as the central focus in clinical trials investigating the role how MSCs can play in the treatment of HF. In this review, we focus on the characteristics of MSCs that give them a distinct edge as cellular therapeutics and present results of clinical trials investigating MSCs in the setting of ischemic HF.

Original languageEnglish (US)
Article number9640108
JournalStem Cells International
Volume2017
DOIs
StatePublished - Jan 1 2017

Fingerprint

Mesenchymal Stromal Cells
Heart Failure
Treatment Failure
Therapeutics
Paracrine Communication
Clinical Trials
Chemokines
Heart Diseases
Signal Transduction
Hospitalization
Fibrosis
Ischemia
Cytokines
Morbidity
Mortality

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

Cellular therapeutics for heart failure : Focus on mesenchymal stem cells. / Pandey, Amitabh C.; Lancaster, Jordan J.; Harris, David T.; Goldman, Steven; Juneman, Elizabeth B.

In: Stem Cells International, Vol. 2017, 9640108, 01.01.2017.

Research output: Contribution to journalReview article

@article{59d2f3c4ec564a7bb3855d9fbb39426f,
title = "Cellular therapeutics for heart failure: Focus on mesenchymal stem cells",
abstract = "Resulting from a various etiologies, the most notable remains ischemia; heart failure (HF) manifests as the common end pathway of many cardiovascular processes and remains among the top causes for hospitalization and a major cause of morbidity and mortality worldwide. Current pharmacologic treatment for HF utilizes pharmacologic agents to control symptoms and slow further deterioration; however, on a cellular level, in a patient with progressive disease, fibrosis and cardiac remodeling can continue leading to end-stage heart failure. Cellular therapeutics have risen as the new hope for an improvement in the treatment of HF. Mesenchymal stem cells (MSCs) have gained popularity given their propensity of promoting endogenous cellular repair of a myriad of disease processes via paracrine signaling through expression of various cytokines, chemokines, and adhesion molecules resulting in activation of signal transduction pathways. While the exact mechanism remains to be completely elucidated, this remains the primary mechanism identified to date. Recently, MSCs have been incorporated as the central focus in clinical trials investigating the role how MSCs can play in the treatment of HF. In this review, we focus on the characteristics of MSCs that give them a distinct edge as cellular therapeutics and present results of clinical trials investigating MSCs in the setting of ischemic HF.",
author = "Pandey, {Amitabh C.} and Lancaster, {Jordan J.} and Harris, {David T.} and Steven Goldman and Juneman, {Elizabeth B}",
year = "2017",
month = "1",
day = "1",
doi = "10.1155/2017/9640108",
language = "English (US)",
volume = "2017",
journal = "Stem Cells International",
issn = "1687-9678",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Cellular therapeutics for heart failure

T2 - Focus on mesenchymal stem cells

AU - Pandey, Amitabh C.

AU - Lancaster, Jordan J.

AU - Harris, David T.

AU - Goldman, Steven

AU - Juneman, Elizabeth B

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Resulting from a various etiologies, the most notable remains ischemia; heart failure (HF) manifests as the common end pathway of many cardiovascular processes and remains among the top causes for hospitalization and a major cause of morbidity and mortality worldwide. Current pharmacologic treatment for HF utilizes pharmacologic agents to control symptoms and slow further deterioration; however, on a cellular level, in a patient with progressive disease, fibrosis and cardiac remodeling can continue leading to end-stage heart failure. Cellular therapeutics have risen as the new hope for an improvement in the treatment of HF. Mesenchymal stem cells (MSCs) have gained popularity given their propensity of promoting endogenous cellular repair of a myriad of disease processes via paracrine signaling through expression of various cytokines, chemokines, and adhesion molecules resulting in activation of signal transduction pathways. While the exact mechanism remains to be completely elucidated, this remains the primary mechanism identified to date. Recently, MSCs have been incorporated as the central focus in clinical trials investigating the role how MSCs can play in the treatment of HF. In this review, we focus on the characteristics of MSCs that give them a distinct edge as cellular therapeutics and present results of clinical trials investigating MSCs in the setting of ischemic HF.

AB - Resulting from a various etiologies, the most notable remains ischemia; heart failure (HF) manifests as the common end pathway of many cardiovascular processes and remains among the top causes for hospitalization and a major cause of morbidity and mortality worldwide. Current pharmacologic treatment for HF utilizes pharmacologic agents to control symptoms and slow further deterioration; however, on a cellular level, in a patient with progressive disease, fibrosis and cardiac remodeling can continue leading to end-stage heart failure. Cellular therapeutics have risen as the new hope for an improvement in the treatment of HF. Mesenchymal stem cells (MSCs) have gained popularity given their propensity of promoting endogenous cellular repair of a myriad of disease processes via paracrine signaling through expression of various cytokines, chemokines, and adhesion molecules resulting in activation of signal transduction pathways. While the exact mechanism remains to be completely elucidated, this remains the primary mechanism identified to date. Recently, MSCs have been incorporated as the central focus in clinical trials investigating the role how MSCs can play in the treatment of HF. In this review, we focus on the characteristics of MSCs that give them a distinct edge as cellular therapeutics and present results of clinical trials investigating MSCs in the setting of ischemic HF.

UR - http://www.scopus.com/inward/record.url?scp=85042479262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042479262&partnerID=8YFLogxK

U2 - 10.1155/2017/9640108

DO - 10.1155/2017/9640108

M3 - Review article

VL - 2017

JO - Stem Cells International

JF - Stem Cells International

SN - 1687-9678

M1 - 9640108

ER -